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Abstract 
Background: Percutaneous coronary interventions (PCI) in coronary artery disease (CAD) with very small vessel 
diameters remains controversial and challenging. These lesions are usually more diffuse, calcified and tortuous. The 
usage of thin strut bare metal stents (BMS) with excellent crossing profiles in a very small caliber coronary lesions has 
increased the likelihood of procedural success.
Objectives: This observational study assessed the 9-month clinical outcomes in an ‘all-comers’ population with very 
small caliber CAD after implantation of thin strut cobalt chromium BMS.
Methods: Thin strut cobalt chromium BMS implantation in a priori pre-defined subgroups was investigated in a non-
randomized, international, multi-center ‘all-comers’ observational study. Primary end-point was the 9-month clinically 
driven target lesion revascularization (TLR) rate. Secondary end-points included the 9-month major adverse cardiac 
event (MACE) and procedural success rates. Data collection was done using an established electronic data acquisition 
form with built-in plausibility checks.
Results: A total of 783 patients with a mean age of 70.4 ± 12.8 years were enrolled, 205 (26.2 %) of them had vessel 
diameters of 2.5 mm and smaller which was defined as CAD with very small reference vessel calibers. Older age and 
diabetics were associated with higher incidences of very small caliber vessels. The mean reference vessel diameter 
in the very small vessel group was 2.05 ± 0.27 mm and mean diameter for vessels >2.5 mm was 3.41 ± 0.55 mm. 
Pre-dilatation was performed more often in the very small vessel patients (52.2 vs. 42.2 %; p value 0.007). There was no 
difference in the overall technical success rates in very small vessel disease group (97.9 vs. 97.7 %). The 9-month TLR 
rate was 6.3 % for the very small vessels and 3.7 % for vessels >2.5 mm (p = 0.129). The 9-month and in-hospital MACE 
rates in the very small vessel group and patient with vessel diameters >2.5 mm were not significantly different (13.1 
vs. 9.2 %; p = 0.1265 and 5.2 vs. 3.7 %; p = 0.349) respectively.
Conclusion: This study has demonstrated that the use of thin strut cobalt chromium BMS in very small vessel CAD 
was reasonably safe and efficacious in the context of ‘real-world’ practice.
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Background
Treatment for very small vessel atherosclerosis with 
revascularization procedures remains a challenge in daily 
clinical practice. Coronary artery bypass grafting (CABG) 
in this group of patients is limited by high rates of graft 
failure (O’Connor et al. 1996) whereas percutaneous cor-
onary interventions (PCI) are associated with increased 
risks of restenosis and adverse clinical outcomes (Elezi 
et  al. 1998). PCI with bare metal stent (BMS) as com-
pared to plain old balloon angioplasty (POBA) in small 
vessel disease only revealed conflicting results and only 
modest superiority of BMS over POBA (Park et al. 2000; 
Kastrati et  al. 2000; Koning et  al. 2001; Agostoni et  al. 
2005). BMS are generally associated with a higher risk 
of in-stent restenosis (ISR). The advances of drug-elut-
ing stent (DES) technology have reduced the risk of in-
stent restenosis (ISR) tremendously (Morton et al. 2003; 
Kirtane et  al. 2009; Park et  al. 2003; Morice et  al. 2002; 
Moses et  al. 2003). However, the incorporation of vari-
ous drugs on the DES platform lead to an effective strut 
thickness increase. Hence, the usage of DES in very small 
vessel may still pose some potential issue including flex-
ibility, deliverability and a continued risk of late and very 
late stent thrombosis (Farooq et al. 2011; Pfisterer et al. 
2006). ISAR-STEREO and ISAR-STEREO 2 trials have 
demonstrated that thinner strut devices are associated 
with a significant reduction of angiographic restenosis 
after coronary artery stenting (Kastrati et al. 2001; Pache 
et al. 2003). Usage of a novel thin strut cobalt-chromium 
BMS (Coroflex® Blue) in a ‘real-world’ setting including 
patients with acute myocardial infarction was proven to 
be safe and efficacious. Event free survival in this cohort 
of patients at 6 months was 90.8 % and the TLR rate for 
ISR at 6 months was 5.5 %. Furthermore, the cumulative 
stent thrombosis rate of 1.6  % and the absence of late 
stent thrombosis within 6 months is remarkably low for 
an all-comer cohort (Bocksch et al. 2010).
Currently, BMS is still used in cases of large luminal 
diameters, acute STEMI, in patients with high bleeding 
risk, anticipated surgical procedures for underlying ill-
ness and in situations where financial limitations may be 
an issue. With the latest stent architecture developments 
in BMS, there is a question whether it is still practical or 
even safe to implant BMS in lesions with very small ves-
sel diameters.
The definition of small vessel coronary arteries involves 
more than an arbitrary upper limit of lumen diameters 
between 2.5 and 2.75  mm. Coronary stenting in small 
vessels has been shown to be safe, feasible and effec-
tive in the long term (Pache et al. 2006). With the avail-
ability of 2.25 and 2.0  mm diameter stents, the term 
very small vessel disease was suggested to those that are 
amenable to PCI with a 2.25 and 2.0 mm device. Despite 
varying definitions in the literature, small vessel coronary 
artery disease (CAD) is highly prevalent. It is estimated 
that approximately 20–30  % of patients with sympto-
matic CAD have small vessel CAD (Biondi-Zoccai et al. 
2007). However, coronary stenting in very small vessels 
(lumen diameter  ≤  2.5  mm) remain controversial and 
challenging.
The objective of this registry was to document the 
safety and efficacy of thin strut BMS in an unselected 
patient population in which BMS implantation was 
deemed reasonable by the treating physician. This obser-
vational study assessed the 9-month clinical outcomes in 
an ‘all comers’ population with a focus lesions with very 
small coronary arteries in a ‘real-world’ setting.
Methods
Thin strut bare metal stenting in a priori defined sub-
groups was investigated. This was a non-randomized, 
international, multi-center ‘all-comers’ observational 
study designed to evaluate the safety and efficacy of the 
thin strut Coroflex® Blue Neo/Ultra coronary stent system 
(B.Braun Vascular Systems, Berlin, Germany). Patients 
were prospectively enrolled in 3 Asian and 17 Euro-
pean centers. In France this study was approved by the 
“Comité Consultative sur le Traitement de I’Information 
en matière de Recherche dans le domaine de la Santé 
(CTIRS dossier no. 12.384) and the Commission Nation-
ale de I’informatique et des Libertés (CNIL, demande 
d’autorisation no. 912431). In Malaysia, this study received 
approval from the University of Malaya Medical Cen-
tre ethics committee, the Universiti Kebangsaan Malay-
sia ethics committee as well as from National Medical 
Research and Ethics Committee. The legal requirements 
are different in the participating countries. Inasmuch 
this clinical assessment was an observational study under 
routine use, the conduct in Germany was regulated by 
the German Device law (Medizin Produkte Gesetz §23b) 
which did not require a formal ethics vote at the time 
this registry was conducted. Likewise in the Netherlands, 
Switzerland and Croatia, ethics votes were not required 
given that data collection was done in a pseudonymized 
manner (no patient initials, only birth years and not birth 
dates). Also these patients would have been treated with 
the device independent of the data collection. The clini-
cal follow-up was part of the routine patient care estab-
lished in each participating country. With the exception 
of France, two votes were mandatory for the collection of 
data and one for the ethical conduct of the study (please 
see the attached documents). The responsibility for the 
documentation of the local requirements was at the indi-
vidual centers. The Declaration of Helsinki was respected 
in all countries. An informed consent text specific to the 
registry approved by the local ethics committees was to 
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be signed by patients prior to their enrolment as man-
dated by the local ethics committees.
Patients aged ≥18  years with stable angina or objec-
tive proof of ischemia or patients with acute coronary 
syndrome (ACS) had to meet the requirements for PCI 
(Windecker et  al. 2014). The decision to implant BMS 
solely depended on the operator preference and experi-
ence. Single or multiple vessel stenting was allowed in de 
novo or re-stenotic lesions. The adjunct treatment with 
drug coating balloons (DCB) was left to the discretion 
of the operator. A maximum lesion length of 28 mm and 
reference vessel diameters from 2.0 to 4.0 mm were per-
missible. Vascular access via the femoral and radial route 
was permitted with recommended introducer sheaths of 
at least 5 French in diameter. Operators could also choose 
direct stenting at their discretion. A standard bolus of 
intravenous heparin (70  IU/kg) was given in all patients 
and supplemented when required. Platelet aggregation 
inhibitor loading was initiated prior to the procedure.
The cobalt chromium Coroflex® Blue Ultra/Neo is 
one of the latest generation coronary BMS character-
ized by its ultra-low strut thickness of 60 μm (Coroflex® 
Blue Neo, vessel diameters from 2.75 to 4.0 mm) and of 
50 μm (Coroflex® Blue Ultra, vessel diameters from 2.0 to 
2.5 mm). The stents are made of implantable, high-grade, 
surgical CoCr alloy (L605, ISO 5832-5 or ASTM F.90) 
with an established biocompatibility. This alloy has been 
successfully used as a material for stents and other sur-
gical implants for many years. The stents were designed 
to improved deliverability in lesions that are extremely 
difficult to cross while reducing the metal volume in the 
treated vessel. The smaller caliber version is made up of 
units with 6 crowns whereas the larger version displays 9 
crowns. Figure 1 showed the illustration of the stent. The 
device is available in lengths of 8–32 mm with a crossing 
profile of less than 0.85 mm.
DES implantation is the standard of care for most 
indications; however, the use of BMS still has a role in 
selected treatment populations particularly in some 
countries where the device costs are covered by the 
patient. Furthermore, in patients who cannot toler-
ate dual antiplatelet therapy (DAPT) for long periods or 
patients with difficult vessel anatomies. The decision to 
use the thin strut BMS was based on the patient’s clini-
cal presentation and on the physician’s preferences (Win-
decker et  al. 2014). The used investigational devices are 
one of the many BMS still being used in ‘real-world’ prac-
tice. The preferred BMS in this observational study has 
the advantage of having thin struts to allow a very favora-
ble lesion crossability in difficult to treat lesions as com-
pared to other less deliverable BMS.
At the discretion of the treating physician clopidogrel 
75 mg/day, prasugrel 10 mg/day or ticagrelor 2 × 90 mg/
day were prescribed at least 1 month post procedure and 
acetylsalicylic acid 100–325 mg/d for life.
In this sub group analysis we are comparing patients 
with very small vessel ≤2.5  mm diameter and vessel 
>2.5 mm diameter. From the previous literature, the defi-
nition of small vessel coronary arteries varies between 
2.5 and 2.75 mm (Pache et al. 2006; Biondi-Zoccai et al. 
2010). With the introduction of 2.0 and 2.25 mm diameter 
stents, any vessel feasible for interventions with 2.0 and 
2.25 mm devices were defined as very small caliber CAD.
Endpoints and definitions
Clinically driven target lesion revascularization (TLR) at 
9-month post procedure as the composite of re-PCI or CABG 
was defined as the primary endpoint. Secondary endpoints 
included major adverse cardiac events (MACE) as the ensem-
ble of TLR, cardiac death and myocardial infarction (MI). 
Rates of definite acute/sub-acute stent thrombosis and proce-
dural success rates were also documented. MI was diagnosed 
with corresponding ECG changes and/or elevated troponin T 
or troponin I. Definite acute/sub-acute stent thrombosis were 
based on the ARC criteria (Cutlip et al. 2007). Cardiac death 
was defined as death from all causes except when the cause 
of death was proven non-cardiac. Procedural success was 
defined as achievement of less than 30 % residual in-segment 
percent diameter stenosis and TIMI flow 3 after the proce-
dure using the assigned device only.
Data collection
All data were collected through a web based data acquisi-
tion system previously used in other observational stud-
ies (Cutlip et al. 2007; Wöhrle et al. 2012; Zeymer et al. 
2014). National principal investigators were responsible 
for the accuracy of their datasets and performed source 
data verification when the routinely performed web 
based plausibility checks indicated discrepancies.
Fig. 1 Coroflex® Blue Ultra stent design (top panel). Coroflex® Blue 
Ultra is made up of units with 6 crowns, Coroflex® Blue Neo with 9 
crowns, crimped stent (bottom panel)
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Statistical analysis
To prove Gaussian distribution, the Kolmogorov–
Smirnov-test was used to justify the calculation of the 
mean and standard deviation unless otherwise indicated. 
Dichotomous variables were evaluated using the chi2-
test while continuous variables were compared with the 
unpaired two-tailed student´s t test. Non-parametric test 
such as the Wilcoxon–Mann–Whitney rank test were used 
whenever applicable. For all tests the significance level α 
was 0.05. Based on prior result with a predecessor device 
(Bocksch et  al. 2010), a literature value of 5.5  % for TLR 
was chosen. With a performance goal margin of +4.0  % 
and an expected 9-month TLR rate of 6.0 % a total of 490 
patients would be needed to detect a difference between 
the null hypothesis proportion and the alternative propor-
tion. A logistic regression model for 9-month MACE was 
implemented for defined cardiovascular risk factors such 
as presence of diabetes or ACS and lesion morphological 
variables such as vessel diameter, lesion length and pres-
ence of calcification. Statistical analyses were done with 
SPSS version 20.0 (IBM, Munich, Germany). The biom-
etric estimate was calculated with nQuery/nTerim version 
2.0 (Statistical Solutions Ltd. Cork, Ireland).
Results
Baseline demographics
A total of 783 patients underwent BMS implantations 
between 1.1.2012 and 31.12.2013. Of these patients, 205 
(26.2 %) have very small vessel diameters (≤2.5 mm) and 
578 (73.8  %) have vessel diameters >2.5  mm (Table  1). 
Patients with very small vessel diameters were older 
(mean age of 72.5  ±  11.3  years vs 69.7  ±  13.1  years) 
more diabetes (31.7 vs 22.8  %) compared to those with 
vessel diameters >2.5 mm. More women (24.4 vs 20.9 %; 
p  =  0.303) and end stage renal disease patients (7.3 vs 
4.0  %; p  =  0.056) were in the very small vessel group. 
Remarkably, 316 (40.4 %) of the overall patients presented 
with ACS, 42.0  % in very small vessel versus 39.8  % in 
vessel diameters >2.5 mm. From the total of 20.8 % who 
had STEMI, 22.4 % with very small vessel versus 20.2 % 
with vessel diameters >2.5 mm.
Angiographic characteristics, procedural data 
and co‑medication
Baseline angiographic characteristics and procedural data 
are shown in Table  2. There was a total of 880 coronary 
lesions which were treated during this study. 247 (28.1 %) 
lesions treated were in very small vessels primarily in the 
left anterior descending artery (39.7 %) and left circumflex 
artery (37.2  %). Of note, 40.1  % of the total lesions were 
complex (type B2/C) according to the modified American 
College of Cardiology (ACC) and American Heart Associa-
tion (AHA) classification (Ryan et al. 1998). Smaller vessel 
lesions trended to be more diffusely diseased with higher 
calcium burden. Pre-dilatation was performed more often 
in the very small vessels (52.2  %) as compared to vessel 
diameters >2.5 mm (42.2 %). The mean reference diameter 
for very small vessel group was 2.05 ± 0.27 mm; whereas the 
mean reference diameter for vessel diameters >2.5 mm was 
3.41 ± 0.55 mm. There was no difference in terms of stent 
balloon inflation pressure (very small vessel 14.8 ± 3.1 atm 
vs. vessel diameters >2.5 mm 15.1 ± 3.0 atm) and the overall 
Table 1 Patient demographics
DVT deep vein thrombosis, PE pulmonary embolism
Variable All patients Vessel diameters 
≤2.50 mm
Vessel diameters  
>2.5 mm
p value small versus  
large vessel diameters
Number of patients 783 205 (26.2 %) 578 (73.8 %) –
Number of lesions 880 247 633 –
Number of BMS used 1027 286 741 –
Age (years) 70.4 ± 12.8 72.5 ± 11.3 69.7 ± 13.1 0.008
Male gender 612 (78.2 %) 155 (75.6 %) 457 (79.1 %) 0.303
Diabetes 197 (25.2 %) 65 (31.7 %) 132 (22.8 %) 0.012
Hypertension 502 (64.1 %) 133 (64.9 %) 369 (63.8 %) 0.790
Cardiogenic shock 38 (4.9 %) 14 (6.8 %) 24 (4.2 %) 0.125
End stage renal disease 38 (4.9 %) 15 (7.3 %) 23 (4.0 %) 0.056
Atrial fibrillation 98 (12.5 %) 20 (9.8 %) 78 (13.5 %) 0.165
Mechanical heart valve 10 (1.3 %) 2 (1.0 %) 8 (1.4 %) 0.655
Documented DVT and/or PE 4 (0.5 %) 1 (0.5 %) 3 (0.5 %) 0.957
Acute coronary Syndrome (ACS) 316 (40.4 %) 86 (42.0 %) 230 (39.8 %) 0.588
STEMI 163 (20.8 %) 46 (22.4 %) 117 (20.2 %) 0.506
NSTEMI 153 (19.5 %) 40 (19.5 %) 113 (19.6 %) 0.991
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technical success rate in very small vessel group was 97.9 
versus 97.7  % in the patient group with vessel diameters 
>2.5 mm. The new oral antiplatelet drugs prasugrel/aspirin 
and ticagrelor/aspirin were administered more frequently in 
the very small vessel (11.2 vs 9.5 %) and (7.8 vs 2.4 %) com-
pared to vessel diameters >2.5  mm respectively (Table  3). 
The duration of dual antiplatelet therapy (DAPT) between 
the two groups were not statistically different.
Clinical outcomes
Overall follow-up at 9 months was 93.9 %. The 9-month 
TLR rate was 6.3  % for very small vessels and 3.7  % 
for vessels >2.5  mm (p  =  0.129). Figure  2 showed the 
Kaplan–Meier curve for freedom from TLR. The log-
rank test revealed no statistical difference with p = 0.112. 
9-month and in-hospital MACE between very small 
vessels and vessels >2.5  mm were not significantly dif-
ferent either (13.1 vs 9.2 %; p = 0.1265 and 5.2 vs 3.7 %; 
p = 0.349) respectively. There was no case of acute stent 
thrombosis observed in either group (Table 4).
Discussion
Vessel size remains an important determinant of adverse 
outcomes even in the DES era (Togni et al. 2007). While 
DES are consistently less prone to restenosis, efforts are 
being made to narrow the efficacy gap between BMS and 
DES. Clinical studies have shown the potential advan-
tage of thinner stent struts in reducing the restenosis 
rate (Suttorp et al. 2015). Although DES are preferred as 
a default treatment strategy, BMS are still implanted for 
reasons such as limited financial resources in some Asian 
countries or contraindications to prolonged DAPT. There 
is limited data on PCI in very small vessels involving ‘real-
world’ patients. The Arthos Pico Austrian Multi-center 
registry recruited 203 all-comer patients with average 
stent diameter of 2.58 ± 0.22 mm with a device delivery 
success rate of 98.0 %. The patients were followed up for 
6 months whereas the overall MACE rate was 13.0 % with 
cumulative TLR of 6.0  % (Strehblow et  al. 2007) which 
was higher than the TLR rate in this study. In this context 
a word of caution is indicated when comparing clinical 
Table 2 Lesion characteristics and procedural data
Variable All patients Vessel diameters 
≤2.50 mm
Vessel diameters  
>2.5 mm
p value small versus  
large vessel diameters
Number of lesions 880 247 633 –
Target vessel <0.001
LAD 290 (33.0 %) 98 (39.7 %) 192 (30.3 %)
CX 233 (26.5 %) 92 (37.2 %) 141 (22.3 %)
RCA 344 (39.1 %) 55 (22.3 %) 289 (45.7 %)
graft 13 (1.5 %) 2 (0.8 %) 11 (1.7 %)
Total occlusion 107 (12.2 %) 33 (13.4 %) 74 (11.7 %) 0.496
Chronic total occlusion 22 (2.5 %) 8 (3.2 %) 14 (2.2 %) 0.381
Thrombus burden 116 (13.2 %) 30 (12.1 %) 86 (13.6 %) 0.570
Diffuse vessel disease 442 (50.2 %) 140 (56.7 %) 302 (47.7 %) 0.017
Calcification 297 (33.8 %) 104 (42.1 %) 193 (30.5 %) 0.001
Ostial lesion 47 (5.3 %) 15 (6.1 %) 32 (5.1 %) 0.546
Bifurcation lesion 51 (5.8 %) 12 (4.9 %) 39 (6.2 %) 0.457
Severe tortuosity 104 (11.8 %) 36 (14.6 %) 68 (10.7 %) 0.114
AHA/ACC type B2/C lesion 353 (40.1 %) 104 (42.1 %) 249 (39.3 %) 0.451
Reference diameter (mm) 3.03 ± 0.53 2.05 ± 0.27 3.41 ± 0.55 <0.001
Lesion length 14.7 ± 7.8 14.7 ± 7.3 14.8 ± 8.0 0.950
Degree of stenosis (%) 86.3 ± 10.7 87.0 ± 9.7 86.0 ± 11.0 0.233
Pre-dilatation 396 (45.0 %) 129 (52.2 %) 267 (42.2 %) 0.007
BMSs used 1027 286 741 –
BMS diameter (mm) 3.02 ± 0.51 2.48 ± 0.25 3.23 ± 0.42 <0.001
BMS length (mm) 16.0 ± 5.9 15.7 ± 5.8 16.1 ± 5.9 0.399
BMS inflation pressure (atm) 15.0 ± 3.1 14.8 ± 3.1 15.1 ± 3.0 0.144
Additional DCB 17 (1.7 %) 3 (1.0 %) 14 (1.9 %) 0.344
Final result  % stenosis 1.7 ± 10.0 1.7 ± 11.0 1.7 ± 9.7 0.430
Overall technical success 1004 (97.8 %) 280 (97.9 %) 724 (97.7 %) 0.849
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event rates across studies. Particularly in the case of small 
caliber vessels, restenosis may be asymptomatic and 
therefore difficult to be detected unless an angiographic 
follow-up is routinely conducted. 
PCI in very small vessels are often considered contro-
versial because (1) very small vessels are responsible for 
the perfusion of a small coronary territory (2) they may 
not be worthwhile for stenting (3) they have a higher 
risk of dissection, perforation (4) or restenosis (5) and 
they are technically more challenging in terms of lesion 
crossability. The clinical relevance of very small vessel 
CAD should be interpreted within the clinical framework 
of the individual patient. The procedural success rate 
improved significantly with novel designs of newer gen-
eration BMS. In our study, we have found that the techni-
cal success in delivering the BMS into very small vessels 
was on the same high level with 97.9 % as compared to 
the patient group with vessels >2.5 mm (97.7 %). A higher 
percentage of very small vessel lesions received pre-dila-
tation, likely because of higher calcification burden and 
diffuse vessel disease. However, stent inflation pressures 
did not differ in both groups.
One of the known advantages of BMS is the duration 
of DAPT post PCI. The risk of stent thrombosis in DES 
is often related to non-compliance or premature cessa-
tion of DAPT. Hence, if compliance to DAPT becomes a 
concern, BMS could be a reasonable option. In this study, 
we have shown that BMS performed equally well when 
implanted in very small vessels as compared larger ves-
sels. The implication would be shorter duration of DAPT 
in patients undergoing elective PCI with BMS. How-
ever, this duration may need to be prolonged in patients 
undergoing PCI in the setting of ACS.
Furthermore, in special populations like the Asian 
patients, with higher prevalence of diabetes mellitus 
(Ahmad et al. 2013), the elderly and females usually have 
diffuse and very small vessel disease. The distal parts of 
the artery when the artery are very small, tortuous and 
calcified there may be an issue with deliverability of the 
stent for some patients, thus new generation thin strut 
BMS can be considered.
Limitations
This study has several limitations. First of all, this is a 
single-group, non-randomized design, which may have 
some degree of selection bias. The indication for BMS 
Table 3 Peri-procedural drug therapy
OAC oral anti-coagulation









Aspirin 783 (100 %) 205 (100.0 %) 578 (100.0 %) 0.009
Clopidogrel 663 (84.7 %) 164 (80.0 %) 499 (86.3 %)
Prasugrel 78 (10.0 %) 23 (11.2 %) 55 (9.5 %)
Ticagrelor 30 (3.8 %) 16 (7.8 %) 14 (2.4 %)
Ticlopidine 2 (0.3 %) 0 (0.0 %) 2 (0.3 %)
GP IIb/IIIa inhibitors 10 (1.3 %) 2 (1.0 %) 8 (1.4 %)
Oral anti-coagulation None 694 (88.6 %) 188 (91.7 %) 506 (87.5 %) 0.106
Vitamin K antagonist (VKA) 74 (9.5 %) 12 (5.9 %) 62 (10.7 %)
New oral anticoagulation 
(NOAC) rivaroxaban
15 (1.9 %) 5 (2.4 %) 10 (1.7 %)
Triple Therapy 
(OAC + DAPT)
OAC + Aspirin + Clopidogrel 70 (8.9 %) 14 (6.8 %) 56 (9.7 %) 0.451
OAC + Aspirin + Prasugrel 2 (0.3 %) 0 (0.0 %) 2 (0.3 %)
OAC + Aspirin + Ticagrelor 1 (0.1 %) 0 (0.0 %) 1 (0.2 %)
Fig. 2 Kaplan–Meier curve for freedom from TLR in very small vessels 
versus larger vessels
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implantations may differ on a country basis depending 
on the risk profile for individual patients. Decisions may 
also have been impacted by local device costs in some 
countries. Data analysis is hence descriptive in nature and 
inferior to a randomized trial as no direct comparison 
can be made versus a control group. Secondly, the results 
reported here may have been affected by the type of bias 
inherent in all registries, namely the selective inclusion of 
lower-risk patients, together with less exhaustive moni-
toring than that applied in randomized controlled trials, 
potentially contributing to an overall under-reporting of 
events. Moreover, mandatory clinical, in-hospital follow-
ups would have been preferred over telephone interviews; 
however, the regulatory ramification of this protocol 
modification would have rendered this study to be unfea-
sible. The follow-up rate of 93.9 % in this registry might be 
able to compensate for some of these deficits. Lastly the 
sample size calculation was based on the 9-month TLR 
rate of the overall population. Consequently, the descrip-
tive nature of this subgroup analysis without the claim of 
proper statistical power must be mentioned as well.
Conclusion
Ultra-thin strut cobalt chromium BMS can be used in 
coronary artery disease (CAD) of very small reference 
diameters with very a high procedural success rates. A 
difference in clinical event rates despite differences in 
cardiovascular risk factors and lesion characteristics was 
not observed. However, PCI with DES remains the stand-
ard of care unless cost issues have an impact on the deci-
sion making process.
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Table 4 Clinical outcomes
Variable All patients Vessel diameters 
≤2.50 mm
Vessel diameters  
>2.5 mm
p value small versus  
large vessel diameters
Number of patients 783 205 (26.2 %) 578 (73.8 %) –
Patients with clinical follow-up 735 (93.9 %) 191 (93.2 %) 544 (94.1 %) 0.627
Follow-up time (months) 9.5 ± 2.4 9.4 ± 2.1 9.6 ± 2.5 0.427
Time to discharge (days) 4.0 ± 12.8 6.0 ± 23.7 3.3 ± 4.7 0.014
In hospital MACE 30 (4.1 %) 10 (5.2 %) 20 (3.7 %) 0.349
In hospital TLR 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) –
In hospital MI 17 (2.3 %) 4 (2.1 %) 13 (2.4 %) 0.815
In hospital cardiac death 13 (1.8 %) 6 (3.1 %) 7 (1.3 %) 0.094
9-month MACE 75 (10.2 %) 25 (13.1 %) 50 (9.2 %) 0.126
9-month TLR (Re-PCI, CABG) 32 (4.4 %) 12 (6.3 %) 20 (3.7 %) 0.129
9-month CABG 5 (0.7 %) 1 (0.5 %) 4 (0.7 %) 0.759
9-month MI 38 (5.2 %) 11 (5.8 %) 27 (5.0 %) 0.669
9-month cardiac death 21 (2.9 %) 8 (4.2 %) 13 (2.4 %) 0.199
9-month stroke rate 3 (0.4 %) 1 (0.5 %) 2 (0.3 %) 0.771
9-month total definite/probable stent 
thrombosis
11 (1.4 %) 5 (2.6 %) 6 (1.1 %) 0.138
Acute stent thrombosis, ≤24 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) –
Subacute stent thrombosis,1-30 d 1 (0.1 %) 0 (0.0 %) 1 (0.2 %) 0.553
Late stent thrombosis, ≥30 d 10 (1.3 %) 5 (2.6 %) 5 (0.9 %) 0.081
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Impact on daily practice
In ‘real-world’ practice, ultra-thin struts high end BMS with excellent crossing 
profiles may be considered as an alternative to DES in CAD with very small 
reference vessel diameters when deliverability, DAPT interruption, bleeding 
risks, or cost may be a concern.
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